Full Press Release Details
Zymeworks Showcases Preclinical Assets, Including New Therapeutic Platform, ProTECT ™ , and Zanidatamab Mechanisms of Action at AACR Annual Meeting.
ZYME
Zymeworks Showcases Preclinical Assets, Including New Therapeutic Platform, ProTECT ™ , and Zanidatamab Mechanisms of Action at AACR Annual Meeting
Key Takeaway: Zymeworks Showcases Preclinical Assets, Including New Therapeutic Platform, ProTECT ™ , and Zanidatamab Mechanisms of Action at AACR Annual Meeting